Pharming Group

Pharming Group N. V. is a biopharmaceutical company focused on developing and commercializing innovative protein replacement therapies and precision medicines for patients with rare diseases. Founded in 1988 in Leiden, Netherlands, Pharming Group N.

V. develops treatments for rare diseases, with its headquarters located in Leiden. The company operates independently and has not undergone any notable mergers or acquisitions. Sijmen De Vries serves as the CEO.

Pharming has engaged in 19 funding rounds, with the most recent being a VENTURE DEBT round in May 2017, raising EUR 15. 60 mn from Oxford Finance Corporation and Silicon Valley Bank, contributing to a total of EUR 16. 50 mn raised. Pharming Group N.

V. specializes in the development and commercialization of innovative protein replacement therapies aimed at addressing unmet needs in patients with rare diseases. Its flagship product, Ruconest, is a recombinant C1 esterase inhibitor used for treating acute hereditary angioedema attacks. The company is expanding its pipeline to include therapies for other rare diseases, such as APDS (Activated PI3K Delta Syndrome), distributing products primarily in European markets, including Germany and France, as well as in the United States.

In the most recent financial year, 2023, Pharming Group reported revenue of EUR 245. 32 mn and an EBITDA of EUR 10. 54 mn, primarily generated from the sales of Ruconest and supported by direct sales agreements with healthcare institutions and specialty distributors. Pharming Group aims to launch new products targeting additional rare diseases and expand its geographic presence in North America and Europe.

The recent funding from the VENTURE DEBT round will support these initiatives, although further specifics on product launches and market expansion timelines have not been disclosed.